1. Receptor-based targeting of therapeutics
   Neelesh Kumar Mehra et al, 2013, Therapeutic Delivery CrossRef
2. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma
   Anne V. Yagolovich et al, 2022, International Journal of Molecular Sciences CrossRef
3. Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
   Agathe Dubuisson et al, 2017, Antibodies CrossRef
4. MRI-guided liposomes for targeted tandem chemotherapy and therapeutic response prediction
   Lili Ren et al, 2016, Acta Biomaterialia CrossRef
5. Differentially cross-linkable core–shell nanofibers for tunable delivery of anticancer drugs: synthesis, characterization and their anticancer efficacy
   S. Uday Kumar et al, 2014, RSC Adv. CrossRef
6. The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells
   Christina Cho et al, 2016, BMC Cancer CrossRef
7. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo
   Xiaofei Wang et al, 2017, Amino Acids CrossRef
8. FERM domain‐containing protein FRMD5 regulates cell motility via binding to integrin β5 subunit and ROCK1
   Jinxia Hu et al, 2014, FEBS Letters CrossRef
9. AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
   Yu Gu et al, 2021, Advanced Science CrossRef
10. Apoptosis and apoptotic body: disease message and therapeutic target potentials
    Xuebo Xu et al, 2019, Bioscience Reports CrossRef